Achieving Treatment Goals in Rheumatoid Arthritis
Release Date: December 14, 2010
Expiration Date: December 14, 2012
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 30 minutes
Description
A unique online case approach that uses a treatment-path analysis to present realistic and interactive simulations based on an actual patient.
Objectives
After completing this learning activity, the participant will be able to:
- Discuss the data showing that biologic-targeted therapies induce remission in signs and symptoms and halt the radiographic progression of moderate to severe RA.
- Critically appraise the evidence that biologic-targeted therapies induce remission in signs and symptoms and halt the radiographic progression of RA in patients failing conventional disease-modifying antirheumatic drug (DMARD) therapy.
- Describe the factors involved in optimizing the choice, timing, and chronology of clinical responses to first- and second-line biologic-targeted therapies for RA.
- Analyze the data that treating RA to achieve a target of prespecified disease activity level is associated with better outcomes than treating RA specifically to control symptoms.
Target Audience
The activity is intended for rheumatologists, rheumatology fellows, and other interested healthcare professionals.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, Ohio
Jonathan Kay, MD
Director of Clinical Research
Division of Rheumatology
Professor of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship that, in the context of their presentation, could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting: |
Bristol-Myers Squibb |
|
| Consulting, Teaching & Speaking: |
Abbott Laboratories; Amgen; Centocor; Genentech/Roche; Pfizer |
|
| Jonathan Kay, MD | ||
| Consulting: |
Genentech; UCB | |
| Consulting, Independent contractor (including contracted research): |
Bristol-Myers Squibb; Roche Pharmaceuticals; Sanofi Aventis |
|
| Consulting, Membership on advisory committee or review panels: |
Centocor |
|
All other planners, CME staff, and content reviewers, have no relevant financial relationship to disclose.
The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:
Genentech & Biogen Idec
| Because of advanced features in this activity, we require a login prior to viewing the activity. Your progress will be saved if you decide to stop and continue at a later time. |
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education
and the R.J. Fasenmyer Center for Clinical Immunology
